Clarivate Plc

Clarivate Plc engages in the provision of global information, analytics and workflow solutions. It operates through the Science and Intellectual Property segments. The Science segment is composed of the academia and government, and life science and healthcare product lines. The Intellectual Property segment includes the patent, trademark, domain, and IP management product lines. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clarivate Plc reports strong Q4 earnings, eyes growth opportunities

Clarivate Plc delivered strong financial results in Q4 2022, driven by the successful ProQuest acquisition and solid organic growth across segments. The company is focused on achieving higher organic growth, reducing leverage, and leveraging culture for success.
While facing macroeconomic challenges and pricing pressures, Clarivate Plc is confident in its strategic plans and capital structure initiatives. Opportunities lie in leveraging AI, enhancing product offerings, and capitalizing on the positive pricing environment.
Navigating challenges such as tough comps, managing inflation impact, and balancing quarterly patterns will be crucial. The company's proactive approach to growth, focus on customer value, and upcoming Investor Day position it well for future success.

Clarivate Plc reports stable Q1 performance amidst growth challenges

Clarivate Plc's Q1 2023 performance showcased stable revenue, strong margins, and strategic financial initiatives despite challenges in net income and organic growth cadence.
The company's strengths lie in market engagement, AI innovation, maintained outlook, and effective pricing strategies, positioning it for continued growth.
Challenges include earnings volatility, execution hurdles in growth projections, and longer-term segment revenue impacts, necessitating strategic planning and operational focus.
Opportunities in AI applications, cash flow utilization, revenue drivers, and segment progress offer avenues for revenue diversification, growth investments, and market expansion.

Clarivate Plc faces revenue challenges but drives growth through innovation

Clarivate Plc's Q2 performance saw challenges in key segments impacting revenue and outlook, despite operational improvements and strategic initiatives.
While facing hurdles in patent annuities and commercialization subsegment growth, the company focuses on sustainability, product innovations, and customer-centric strategies for future growth.
Detailed financial results and revised guidance reflect the company's proactive approach to address challenges and capitalize on opportunities for sustainable growth.
With a pivot around three segments and emphasis on higher-touch sales, Clarivate aims to navigate challenges, leverage opportunities, and drive revenue growth in the evolving market landscape.

Clarivate Plc reports Q3 growth, tackles challenges, eyes tech acquisitions

Clarivate Plc's Q3 performance showed growth in key segments despite challenges in IP and LS&H businesses.
Opportunities lie in technology acquisitions, analytic platforms, and direct sales to pharma companies.
Management remains optimistic about quarterly results and progress, focusing on enhancing growth strategies.

Clarivate Plc reports solid Q4 performance amidst sector challenges

Clarivate Plc's Q4 2023 performance reflects progress in key segments and a strategic focus on organic growth and operational efficiencies.
While facing challenges in the A&G segment and market conservatism, the company is leveraging strengths in Life Sciences investments and pricing strategies.
Opportunities lie in growth acceleration through new offerings, improved organic growth, and renewed optimism in the life sciences sector.

Clarivate Plc reports Q1 revenue growth, eyes segment expansion

Clarivate Plc's Q1 performance showed promising organic revenue growth and steady renewal rates, with a focus on future investments for growth.
While facing financial challenges and neutral market conditions, the company sees opportunities in segment growth and real-world data solutions.
Overall, Clarivate remains on track with full-year guidance, aiming for 1% organic growth and focusing on driving subscription business growth.

Clarivate Plc reports mixed Q2 results, focuses on growth strategies

Clarivate Plc reported mixed financial results in Q2 2024, with slight revenue growth but challenges in certain segments.
Management emphasized resilience in adjusted EPS and operating cash flow, focusing on growth plans and operational improvements.
Analysts raised concerns about project delays and segment performance, but opportunities in product innovation and revenue growth were highlighted.
The company aims to drive subscription revenue growth through upcoming product releases and investment in business.

Clarivate Plc faces revenue decline in Q3 but focuses on growth strategies

Clarivate Plc's Q3 2024 earnings call highlighted challenges in revenue decline and net loss, with a focus on repositioning and value creation. The company is implementing a Value Creation Plan to optimize its business model and drive sustainable growth. Opportunities exist in improving sales execution, product innovation, and aligning the portfolio for enhanced profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clarivate Plc engages in the provision of global information, analytics, and workflow solutions. It operates through the following segments: Academia and Government (A&G), Intellectual Property (IP), and Life Sciences and Healthcare (LS&H). The A&G segment involves the provision of research and analytics, content aggregation, and workflow software solutions using artificial intelligence. The IP segment includes the maintenance, intelligence, and management solutions. The LS&H focuses on solutions for research and development, regulatory and safety, and commercialization. The company was founded in 1864 and is headquartered in London, the United Kingdom.

LONDON , June 27, 2024 /PRNewswire/ --  Clarivate Plc  (NYSE:CLVT), a leading global provider of transformative intelligence, today released a Global Research Report from the Institute for Scientific Information (ISI)™. The report integrates and interprets multiple data sources from across Clarivate™ portfolios to highlight the academic and societal benefits of the rapidly evolving landscape of digital health.

Clarivate Report Demonstrates Societal Impact of Digital Health Research and Innovation Growth

Guidewire Software

Jones Lang LaSalle

Pinterest

Tenet Healthcare

Goldman Sachs NYSE: GS released a list of their top 50 stocks based on expected AI-driven earnings leverage. The firm ranked companies across sectors according to forecasted productivity gains linked to AI-powered automation.

Top 5 Stocks to Watch for AI-Driven Gains That Aren't NVIDIA

Enabling users to save time and reduce risks in the IP filing and prosecution process LONDON , June 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today launched the IP Collaboration Hub™ at the 2024 Clarivate Ignite conference held in San Diego, U.S. The new solution integrates with Clarivate IP management systems (IPMS) to provide a central hub for collaborating with local agents worldwide. The IP Collaboration Hub enables users to save time and reduce risks in the IP filing and prosecution process by providing a portal for instructors and local agents to collaborate and exchange information, while automatically docketing everything in the IPMS.

Clarivate Launches IP Collaboration Hub

Adds Emerging Sources Citation Index™ for a simplified and unified category view LONDON , June 20, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the 2024 update to the Journal Citation Reports™ (JCR™). The reports provide an essential and comprehensive resource of high-quality journals, ranked by field to enable academic institutions, researchers and publishers to gauge the significance of journals in the global research landscape.

Clarivate Reveals World's Leading and Trusted Journals with the 2024 Journal Citation Reports

Emerging standouts set to transform drug discovery and development, revolutionize cancer treatment, and capture big pharma interest highlighted in third annual report LONDON , June 19, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its annual Companies to Watch report, highlighting seven innovative companies revolutionizing drug discovery and development. These companies are advancing antibody-drug conjugates (ADCs) to deliver highly targeted cancer treatments with minimal side effects.

Clarivate Identifies Seven Innovators in Antibody Drug Conjugates in New Companies to Watch Report

Insights from the new InCites Benchmarking & Analytics module support strategic investment and demonstrate impact LONDON , June 4, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today launched Research Horizon Navigator™, a powerful new AI-native module within InCites Benchmarking & Analytics™ that highlights emerging research topics where future breakthroughs are likely to occur. Academics, funding agencies, government research organizations and research strategists will be able to identify new research trends and determine the most impactful areas for future investments and strategies.

Clarivate Launches Research Horizon Navigator to Pinpoint Future Breakthrough Areas

Strategic collaboration enhances insight into patient demographics and behaviors, enabling analytical precision in addressing population health outcomes LONDON, May 31, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced a strategic partnership with HealthWise Data, a leading healthcare data and analytics firm bridging the gap between clinical outcomes and Social Determinants of Health (SDoH) domains. The collaboration integrates SDoH attributes into the Clarivate Real-World Data repository, offering comprehensive patient insights and enabling life science, healthcare and research professionals to enhance patient outcomes and healthcare equity.

Clarivate Expands Real-World Data Offering with Addition of Social Determinant of Health (SDoH) Attributes from HealthWise Data

LONDON , May 30, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT; CLVT PR A) ("Clarivate"), a leading global provider of transformative intelligence, announced today that its 5.25% Series A Mandatory Convertible Preferred Shares (the "Preferred Shares"), will automatically and mandatorily convert into ordinary shares of Clarivate on June 3, 2024 (the "Conversion Date"). The mandatory conversion rate for each Preferred Share will be 3.8462 ordinary shares of Clarivate.

Clarivate Announces Conversion Date and Conversion Rate for Series A Mandatory Convertible Preferred Shares

Clarivate reported weak 1Q24 results, with revenue falling and organic growth dipping into negative territory. Despite the disappointing results, I still believe Clarivate is an attractive buy, as the weak growth is attributed to macroeconomic factors rather than structural issues. I expect organic growth to recover once the macro environment improves.

Clarivate Plc: Still A Buy, But Recovery Could Take Longer Than Expected

Transforming the way libraries select, acquire and manage their collections of academic books LONDON , May 30, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announces that 500 institutions around the world have selected the Rialto™ books marketplace solution with Florida Atlantic University as the 500th customer. This milestone, achieved in just a few years, underscores Rialto's rapid adoption and success in transforming the way libraries acquire and manage their academic book collections so they can best serve their communities.

Clarivate Celebrates 500 Institutions Adopting Rialto Marketplace Solution

LONDON , May 29, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today announced that the Company will present at the following investor conferences in June 2024: Jonathan Gear, Chief Executive Officer, will present at the William Blair Growth Stock Conference on Tuesday, June 4, 2024, at 2:00 p.m. Central Time (3:00 p.m.

Clarivate to Present at Upcoming Investor Conferences in June 2024

New report highlights innovations poised to drive significant clinical and market impact LONDON , May 22, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of the Medical Technologies to Watch in 2024 report. This first installment of a two-part series offers a comprehensive predictive analysis of high-growth medical technology markets poised to generate over $1 billion in value or achieve double-digit growth within the next five years.

Clarivate Identifies Five Breakthrough Medical Technologies Set to Transform Patient Care in 2024

Analyzing six of the key trademark registers from around the world LONDON , May 21, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released the Trademark Filing and Litigation Trends 2024 Report, analyzing six of the key trademark registers from around the world: the United States (U.S.), the European Union (EU), the United Kingdom (U.K.), Mainland China, Japan, and South Korea. The report reveals that trademark filing activity worldwide saw a return to stability and growth in 2023 after three years of market volatility, indicating solid growth in 2024.

New Clarivate Report Indicates Solid Growth in 2024 Global Trademark Filing Activity

Providing faster and more accurate answers to critical business questions LONDON , May 20, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, launched the first publicly available version of Trademark Watch Analyzer today at the 2024 International Trademark Association Annual Meeting. As the next-generation trademark protection solution enhanced by artificial intelligence (AI) and cloud technology, this solution combines Clarivate global trademark and case law data, in-house IP expertise, and cutting-edge AI technology.

Clarivate Launches AI-Enhanced Solution to Accelerate Trademark Watching

Infringement declined globally from 2012 to 2019 LONDON , May 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released the 2024 Non-Practicing Entity Global Litigation (NPE) Report to analyze NPE enforcement activities and their patent validity challenges across the globe. The report revealed that the United States, Germany and Mainland China are the three countries and regions with the most infringement cases filed by NPEs.

New Clarivate Report Reveals that the U.S., Germany and Mainland China have the most Non-Practicing Entity Litigation

IP solution maximizes operational efficiency for leading automation company LONDON , May 9, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that OMRON has selected IPfolio™, an intellectual property management software from Clarivate to transform their IP operations. This solution will enable OMRON, a leading automation company to make smarter decisions and plan strategically using IP data and analytical insights.

OMRON Selects IPfolio from Clarivate

While the top- and bottom-line numbers for Clarivate (CLVT) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Clarivate (CLVT) Q1 Earnings: A Look at Key Metrics

Clarivate PLC (CLVT) came out with quarterly earnings of $0.14 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.18 per share a year ago.

Clarivate PLC (CLVT) Q1 Earnings Meet Estimates

— Reaffirms 2024 Outlook — LONDON , May 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2024. First  Quarter 2024 Financial Highlights Revenues of $621.2 million decreased 1.3% Organic revenues decreased 1.7%, as an increase in subscription revenues of 2.4% was more than offset by a decrease in transactional and other revenues of 11.4% and re-occurring revenues of 5.1% Net loss attributable to ordinary shares of $93.8 million; Net loss per diluted share of $0.14 Adjusted net income(1) of $103.5 million decreased 20.9%; Adjusted diluted EPS(1) of $0.14 decreased 22.2% or $0.04 Adjusted EBITDA(1) of $236.3 million decreased 6.5%; Adjusted EBITDA margin(1) of 38.0% decreased 220 basis points primarily due to lower revenues Net cash provided by operating activities of $176.2 million decreased $51.3 million; Free cash flow(1) of $111.8 million decreased $56.4 million primarily due to the timing of working capital "We are making great progress this year on key objectives including product investments and operational initiatives to drive future organic revenue growth," said Jonathan Gear, Chief Executive Officer.

Clarivate Reports First Quarter 2024 Results

Empowering  biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for precise market sizing and patient population analysis LONDON , May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions.

Clarivate Introduces Epidemiology Intelligence™ for Precision Patient Population Analysis

Enhancements enable pharma, biotech and generics companies to streamline regulatory tracking and optimize life cycle management for small molecules and biologics  LONDON , May 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking.

Clarivate Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory Success

LONDON , May 1, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT; CLVT PR A) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the "Preferred Shares"), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024. On the mandatory conversion date, which is scheduled to occur on June 3, 2024, each Preferred Share will automatically and mandatorily convert into a number of ordinary shares of Clarivate (and cash in lieu of any fractional ordinary shares) based on the average volume weighted average price ("VWAP") of Clarivate's ordinary shares over a 30-trading day period that begins on, and includes, April 18, 2024 and is scheduled to end on, and include, May 30, 2024 (the "valuation period").

Clarivate Declares Dividend on Mandatory Convertible Preferred Shares

Clarivate (CLVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clarivate PLC (CLVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Three-part report investigates rapid pipeline growth, partnerships, clinical trials ,  and patient access challenges in cancer treatment LONDON , April 30, 2024 /PRNewswire/ -- BioWorld™ published by  Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, explores the growing investment in CAR T therapy development in mainland China in a new series titled " China's CAR T market comes of age." The report examines the dynamic realm of CAR T-cell therapies in China, including the rapid pipeline growth, deals, clinical trials and challenging issues surrounding patient access to very expensive and effective cancer therapeutics.

BioWorld by Clarivate Explores the Future of CAR T Therapy in Mainland China in Special Report

LONDON , April 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announces it has signed the United Nations Sustainable Development Goals (UN SDGs) Publishers Compact. Signatories of the compact pledge to develop sustainable practices and act as champions of the SDGs during the Decade of Action (2020-2030).

News for Clarivate Plc Stock (CLVT)